Evidence mapPaperPMID 40868959Full record

ArticleLife (Basel, Switzerland)2025

Exploring the Proteomic Signature of Diabetic Nephropathy: Implications for Early Diagnosis and Treatment.

Duygu Sari-Ak, Fatih Con, Nazli Helvaci, Hayriye Ecem Yelkenci, Alev Kural, Ozgur Can, Mustafa Caglar Beker

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Duygu Sari-AkDepartment of Medical Biology, Hamidiye International School of Medicine, University of Health Sciences, Istanbul 34668, Turkey.ORCID 0000-0002-1577-7387
Fatih ConClinic of Medical Biochemistry, Bakırkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul 34668, Turkey.ORCID 0009-0006-5966-5201
Nazli HelvaciDepartment of Medical Biochemistry, Hamidiye School of Medicine, University of Health Sciences, Istanbul 34668, Turkey.ORCID 0000-0001-7496-1208
Hayriye Ecem YelkenciRegenerative and Restorative Medical Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul 34810, Turkey.
Alev KuralClinic of Medical Biochemistry, Bakırkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul 34668, Turkey.
Ozgur CanDepartment of Nephrology, İstanbul Haydarpaşa Numune Training and Research Hospital, University of Health Sciences, Istanbul 34668, Turkey.
Mustafa Caglar BekerRegenerative and Restorative Medical Research Center (REMER), Research Institute for Health Sciences and Technologies (SABITA), Istanbul Medipol University, Istanbul 34810, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic nephropathy (DN) is a leading cause of end-stage renal disease, characterized by progressive kidney dysfunction. Early detection and targeted therapies remain key challenges in managing DN. This study aims to identify proteomic alterations in DN patients compared to healthy controls, focusing on proteins involved in inflammation, oxidative stress, immune response, and metabolic dysregulation. Using mass spectrometry and advanced bioinformatics, we identified significant upregulation of proteins associated with platelet activation, immune regulation, and extracellular matrix remodeling, as well as downregulation of proteins linked to lipid metabolism, immune regulation, and structural stability. These findings highlight the molecular complexity of DN and suggest that altered protein expression plays a critical role in the progression of kidney damage. The identified proteins may serve as potential biomarkers for early diagnosis and therapeutic targets for DN. Our results underline the importance of proteomic analyses in advancing the understanding of DN pathogenesis and in developing strategies for personalized treatment to improve patient outcomes. Future research should focus on further elucidating these molecular mechanisms and their implications for clinical management.

Indexed as

biomarkersdiabetic nephropathyinflammationmass spectrometryoxidative stressproteomics

Identifiers

PMID40868959
PMCPMC12387283

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.